Hueda-Zavaleta, M.; Gómez de la Torre, J.C.; Cáceres-Del Aguila, J.A.; Muro-Rojo, C.; De La Cruz-Escurra, N.; Arenas Siles, D.; Minchón-Vizconde, D.; Copaja-Corzo, C.; Bardales-Silva, F.; Benites-Zapata, V.A.;
et al. Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection. Vaccines 2022, 10, 502.
https://doi.org/10.3390/vaccines10040502
AMA Style
Hueda-Zavaleta M, Gómez de la Torre JC, Cáceres-Del Aguila JA, Muro-Rojo C, De La Cruz-Escurra N, Arenas Siles D, Minchón-Vizconde D, Copaja-Corzo C, Bardales-Silva F, Benites-Zapata VA,
et al. Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection. Vaccines. 2022; 10(4):502.
https://doi.org/10.3390/vaccines10040502
Chicago/Turabian Style
Hueda-Zavaleta, Miguel, Juan C. Gómez de la Torre, José Alonso Cáceres-Del Aguila, Cecilia Muro-Rojo, Nathalia De La Cruz-Escurra, Daniella Arenas Siles, Diana Minchón-Vizconde, Cesar Copaja-Corzo, Fabrizzio Bardales-Silva, Vicente A. Benites-Zapata,
and et al. 2022. "Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection" Vaccines 10, no. 4: 502.
https://doi.org/10.3390/vaccines10040502
APA Style
Hueda-Zavaleta, M., Gómez de la Torre, J. C., Cáceres-Del Aguila, J. A., Muro-Rojo, C., De La Cruz-Escurra, N., Arenas Siles, D., Minchón-Vizconde, D., Copaja-Corzo, C., Bardales-Silva, F., Benites-Zapata, V. A., & Rodriguez-Morales, A. J.
(2022). Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection. Vaccines, 10(4), 502.
https://doi.org/10.3390/vaccines10040502
